Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
Abstract
Background: To meet the requirements of the rapidly progressing genetic testing technologies in clinical laboratories, assuring the quality of genetic tests by utilizing appropriate quality control materials is of paramount importance. The CRISPR/Cas9 technology was used to prepare quality control materials because genome‐edited human cell lines are one of the major resources for quality control materials. Methods: In this study, in vitro transcribed sgRNA were transfected into a Cas9‐expressing lymphoblastoid cell line (LCL)—by electroporation—to simulate the SEA‐type deletion observed in α‐thalassemia. The edited positive cell line was screened and identified by polymerase chain reaction (PCR) followed by Sanger sequencing. The whole‐genome sequencing was also performed to show evidence of predicted mutation. Results: The results showed that electroporation of the in vitro transcribed gRNAs into stable Cas9‐expressing LCL was a more efficient gene‐editing technique as compared to plasmid‐mediated transfection, and that the positive rates could reach up to 35.9%. The predominance of indel sizes relative to the predicted deletion length was clustered between 10 and 0 bp. The results of whole‐genome sequencing also demonstrated the existence of SEA‐type deletion of α‐thalassemia. Conclusions: Gene‐editing based on Cas9‐expressing LCL by electroporation of sgRNA was a more efficient approach to introduce mutations for generating quality control materials for genetic testing. The edited lymphoblastoid cell lines were feasible to serve as quality control materials in genetic testing.
Overview
CoChat Summary
TL;DR
This study used CRISPR/Cas9 to introduce a SEA-type α-thalassemia deletion into a Cas9-expressing lymphoblastoid cell line by electroporating in vitro transcribed sgRNAs, aiming to generate quality control materials for genetic testing. The edited cell lines were obtained efficiently and verified by PCR, Sanger sequencing, and whole-genome sequencing.
Key findings
- Electroporation of in vitro transcribed gRNAs into stable Cas9-expressing LCL was more efficient than plasmid-mediated transfection: plasmid groups showed almost no indels, while gRNA transfection gave 10–30% indels by T7EI and positive rates up to 35.9% (28/78).
- sgRNA A1/B1 had higher editing efficiency than sgRNA A2/B2: common editing efficiency was 35.9% (28/78) vs 19.2% (27/141); biallelic deletion was 24.4% vs 12.8%, and monoallelic deletion was 11.5% vs 6.4%.
- Sanger sequencing showed indel sizes from −437 to +483 bp in mutant homozygotes and −100 to +1 bp in mutant heterozygotes, with the preponderance clustered between −10 and 0 bp; precise predicted deletion occurred in 15.8% (6/38) of biallelic and 41.2% (7/17) of monoallelic deletion alleles.
- Whole-genome sequencing of one edited and two WT cell lines yielded 536 Gb of raw data, 255.20–393.46 million reads per clone, >94.85% mapped reads, and 47–72× genome coverage; it revealed a homozygous 19 kb deletion in chr16 consistent with PCR identification.
Methods
- GM12878 cells stably expressing Cas9 and mCherry were cultured in RPMI 1640 with 15% FBS, streptomycin, and penicillin; sgRNAs were designed using CHOPCHOP for SEA-type α-thalassemia at chr16:165301–165501 and chr16:184401–185001, then in vitro transcribed.
- In vitro transcribed gRNAs (12 µg) were electroporated into cells (2 × 10⁶ cells/mL) at 400 V for 30 ms using a 20 µL tube electroporator; editing was assessed by T7EI assay, single-cell sorting, PCR, and Sanger sequencing.
- Genomic DNA from two WT cell lines and one Cas9-edited biallelic deletion line was sequenced on Gene+ Seq-2000 (paired-end 150 bp) with an average 35× sequencing depth; sequences were aligned using BLAST and visualized with IGV.
Limitations
- The paper states that off-target effects may cause false-positive and negative results, and continuous Cas9/sgRNA expression could accumulate off-target sites over time; it also notes that the inserted Cas9 gene might affect DNA detection or genomic stability, though the authors argue this would not influence mutation detection and that genomic stability is comparable.
- The paper states that tolerance for off-target effects varies by application, with therapeutic applications having much lower endurance than preparing QC materials, which are verified before use.
- Evident from the text: validation focused on one SEA-type α-thalassemia deletion in GM12878 cells, and no genome-wide off-target analysis is reported despite whole-genome sequencing; generalizability to other mutations or cell lines is not demonstrated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
0 Valid · 0 Not valid · 11 Not checked · 33 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The range of indel sizes was from −437 to +483 bp in the mutant homozygotes and from −100 to +1 bp in the mutant heterozygotes.”
§ Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing > RESULTS > Analysis of the edited mimetic SEA‐type α‐thalassemia cell line by Sanger sequencing
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“electroporation of the in vitro transcribed gRNAs into stable Cas9‐expressing LCL was a more efficient gene‐editing technique as compared to plasmid‐mediated transfection”
- Also stated in: § Electroporation of in vitro transcribed gRNAs into stable Cas9‐expressing LCL is highly efficient and expedite gene‐editing technique · hedged
“which indicates the latter is a more efficient gene‐editing way”
§ Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Electroporation of in vitro transcribed gRNAs into stable Cas9‐expressing LCL is highly efficient and expedite gene‐editing technique · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the time needed for the workflow was shortened as the transcription of the specific sgRNA had been completed based on the PCR product including T7 promoter and target sequence (Figure S1)”
§ Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing > RESULTS > Electroporation of in vitro transcribed gRNAs into stable Cas9‐expressing LCL is highly efficient and expedite gene‐editing technique
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Almost no indels were detected in the plasmid transfection groups (data not shown)”
§ Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing > RESULTS > Electroporation of in vitro transcribed gRNAs into stable Cas9‐expressing LCL is highly efficient and expedite gene‐editing technique
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the positive rates could reach up to 35.9%”
- Also stated in: § Electroporation of in vitro transcribed gRNAs into stable Cas9‐expressing LCL is highly efficient and expedite gene‐editing technique · plain
“the editing efficiency reached up to 35.9% (28/78)”
§ Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Electroporation of in vitro transcribed gRNAs into stable Cas9‐expressing LCL is highly efficient and expedite gene‐editing technique · plain
22 more claims
Create a free account to see all 44 claims and to verify the 22 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 12
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing > MATERIALS AND METHODS > Genomic DNA isolation and whole‐genome sequencing
“the final libraries were sequenced on Gene + Seq‐2000 (Paired‐end 150 bp) with an average 35 × sequencing depth at the Gene+ company.”
§ Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing > RESULTS > Identification of on‐target mutations at the genome‐wide scale by whole‐genome sequencing
“sequencing depth per clones ranged from 47 to 72 × genome coverage after alignment to the reference genome”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing > RESULTS > Analysis of the edited mimetic SEA‐type α‐thalassemia cell line by Sanger sequencing
“Sanger sequencing of the biallelic deletion clones revealed 14/38 (36.8%) of the single clones to be not completely homozygous based on the differing indels at the predicted deletion sites on each allele. The remaining 24/38 (63.2%) of the biallelic deletion clones had only a single deletion junction identified by sequencing.”
§ Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing > RESULTS > Identification of SEA‐type α‐thalassemia cell line generated by the CRISPR/Cas9 system
“| Biallelic deletion | 19 (24.4%) | 18 (12.8%) | 37 (16.9%) |”
Citations
Cites
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection
Liang, X., Potter, J., Kumar, S., Zou, Y., Quintanilla, R., Sridharan, M., Carte, J., Chen, W., Roark, N., Ranganathan, S., et al. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.04.024 · Cited by 733
Wei, J., Marisetty, A., Schrand, B., Gabrusiewicz, K., Hashimoto, Y., Ott, M., Grami, Z., Kong, L.-Y., Ling, X., Caruso, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121266 · Cited by 396
CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation
Han, X., Liu, Z., Jo, M. C., Zhang, K., Li, Y., Zeng, Z., Li, N., Zu, Y., & Qin, L. (2015) · Science Advances · doi:10.1126/sciadv.1500454 · Cited by 230
Efficient in vivo deletion of a large imprinted lncRNA by CRISPR/Cas9
Han, J., Zhang, J., Chen, L., Shen, B., Zhou, J., Hu, B., Du, Y., Tate, P. H., Huang, X., & Zhang, W. (2014) · RNA Biology · doi:10.4161/rna.29624 · Cited by 168
Self-citationEngineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells
Hung, K. L., Meitlis, I., Hale, M., Chen, C.-Y., Singh, S., Jackson, S. W., Miao, C. H., Khan, I. F., Rawlings, D. J., & James, R. G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.012 · Cited by 134
DIG-Seq: A genome-wide CRISPR off-target profiling method using chromatin DNA
Kim, D., & Kim, J.-S. (2018) · Genome Research · doi:10.1101/gr.236620.118 · Cited by 108
Research works printed but not linked: 1
- https://www.ncbi.nlm.nih.gov/omim. Accessed November 5 2019.
Cited by
Li, R., Zhang, R., Tan, P., Wang, M., Chen, Y., Zhang, J., Han, D., Han, Y., Li, J., & Zhang, R. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23746 · Cited by 3
Self-citationYang, Z., Huang, X., Sun, H., Bian, C., Lin, K., & Zhe, J. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2023-0035 · Cited by 3
Li, J., Zhang, K., Han, Y., Peng, R., Li, L., Li, J., & Lin, G. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00837-24 · Cited by 2
Self-citationZhang, H., Han, L., Feng, Y., Yang, L., Qiu, Y., Zhang, C., Li, T., Ke, P., Kong, Q., Liu, Y., et al. (2026) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2026.101317
Metadata
- Authors
- Zhou, L., Li, R., Zhang, R., Peng, R., Chen, K., Gao, P., Zhang, J., Zhang, R., & Li, J.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Hospital (CN)
- Corresponding author
- Zhang, Rui
- Li, Jinming
- Venue
- Journal of Clinical Laboratory Analysis
- Publisher
- Wiley
- Published
- 2020-03-02
- Volume
- 34
- Issue
- 7
- Pages
- e23256-e23256
- ISSN
- 0887-8013 (ISSN-L)
- 1098-2825
- PMC
- PMC7370731
- OpenAlex
- W3009396600
- Semantic Scholar
- f2f8cd42d37f188b9eb28e7658c5fabbcbe34dd3
- Cited by
- 4
- References
- 28
- Citations by year
- 2026: 1 · 2024: 2 · 2021: 1
- FWCI
- 0.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Laboratory Analysis (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81871721)
- Chinese Academy of Medical Sciences (2018RC320014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- CRISPR/Cas9, lymphoblastoid cell lines, quality control materials, genetic testing, alpha-thalassemia, genome editing, electroporation, single guide RNA, whole genome sequencing
- MeSH terms
- Gene Editing, Whole Genome Sequencing, CRISPR-Associated Protein 9, RNA, Guide, CRISPR-Cas Systems, Cell Line, Genetic Testing, Humans, Mutation, Quality Control, Transfection, alpha-Thalassemia, Electroporation, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing. https://app.cochat.ai/papers/10.1002/jcla.23256
- The paper
- Zhou, L., Li, R., Zhang, R., Peng, R., Chen, K., Gao, P., Zhang, J., Zhang, R., & Li, J. (2020). Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.23256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.